A Summary: Previously, it had been observed that nitric oxide (NO) contributes to hypoxia-induced pial artery dilation in the newborn pig, Additionally, it was also noted that activation of ATP-sensitive K+ channels (K ATP ) contribute to cGMP
mediated as well as to hypoxia-induced pial dilation, Although somewhat controversial, adenosine is also thought to contribute to hypoxic cerebrovasodilation. The present study was de signed to investigate the role of NO, cyclic nucleotides, and activation of K A T P channels in the elicitation of adenosine's vascular response and relate these mechanisms to the contribu tion of adenosine to hypoxia-induced pial artery dilation. The closed cranial window technique was used to measure pial diameter in newborn pigs. Hypoxia-induced artery dilation was attenuated during moderate (Pa02 '" 35 mm Hg) and severe hypoxia (P a02 '" 25 mm Hg) by the adenosine receptor antago nist 8-phenyltheophyUine (8-PT) (10-5 M) (26 ± 2 vs. 19 ± 2 and 34 ± 2 vs. 22 ± 2% for moderate and severe hypoxia in the absence vs. presence of 8-PT, respectively). This concentration of 8-PT blocked pial dilation in response to adenosine (8 ± 2, 16 ± 2, and 23 ± 2 vs. 2 ± 2, 4 ± 2, and 6 ± 2% for IO-H, 10-6 , and 10-4 M adenosine before and after 8-PT, respectively). Similar data were also obtained using adenosine deaminase as Although somewhat controversial, adenosine is gen erally thought to contribute to hypoxic cerebrovasodila tion. For example, adenosine concentration has been ob served to increase during hypoxia in brain tissue and interstitial fluid of the adult rat (Van Wylen et aI., 1986; Winn et aI., 1981) , while the adenosine receptor antago nist, theophylline, attenuated hypoxic hyperemia in the a probe for the role of adenosine in hypoxic pial dilation. Aden osine-induced dilation was associated with increased CSF cGMP concentration (390 ± 11 and 811 ± 119 fmol/ml for control and 10-4 M adenosine, respectively). The NO synthase inhibitor, L-NNA, and the cGMP antagonist, Rp 8-bromo cGMPs, blunted adenosine-induced pial dilation (8 ± I, 14 ± 1, and 20 ± 3 vs. 3 ± 1, 5 ± 1, and 8 ± 3% for 10-8 , 10-6 , and 10-4 M adenosine before and after L-NNA, respectively). Adenosine dilation was also blunted by glibenclamide, a K ATP antagonist (9 ± 2, 14 ± 3, 21 ± 4 vs. 4 ± 1, 8 ± 2, and 11 ± 2% for 10-8 , 10-6 , and 10-4 M adenosine before and after glibenclamide, respectively). Finally, it was also observed that adenosine induced dilation was associated with increased CSF cAMP concentration and the cAMP antagonist, Rp 8-bromo cAMPs, blunted adenosine pial dilation. These data show that adenosine contributes to hypoxic pial dilation. These data also show that NO, cGMP, cAMP, and activation of K A T P channels all con tribute to adenosine induced pial dilation. Finally, these data suggest that adenosine contributes to hypoxia-induced pial ar tery dilation via cAMP and activation of K ATP channels by NO and cGMP. Key Words: Newborn-Cerebral circulation. adult dog (Emerson and Raymond, 1981) and pial artery dilation in the adult rat (Morii et aI., 1987) . On the other hand, 8-phenyltheophylline and adenosine deaminase had no effect on the cerebral hyperemic response to hyp oxia in the adult cat or rat (Reid et aI., 1995; Dora et aI., 1984) . The role of adenosine in hypoxic cerebrovasodi lation has been less well characterized in the newborn, but the observations have been equally inconsistent. For example, brain interstitial fluid adenosine concentration is increased during hypoxia in the newborn pig (Park et aI., 1987) and 8-phenyltheophylline attenuates hypoxic hyperemia while adenosine deaminase blunted hypoxic dilation in the newborn pig (Laudignon et aI., 1990; Wa gerele and Mishra, 1986) . Alternatively, theophylline was also observed to have no effect on hypoxic hyper emia in the newborn pig (McPhee and Maxwell, 1987) .
Several other mechanisms have also been suggested to be involved in hypoxic cerebrovasodilation. For ex ample, nitric oxide (NO) synthase inhibitors have been reported to attenuate the increase in cerebral blood flow and pial artery dilation elicited by hypoxia in the adult (Iwamoto et aI., 1992) and newborn pig (Armstead, 1995a) , while fL and 5 opioid receptor antagonists at tenuate hypoxic pial dilation in the piglet (Armstead, 1995a,b) . Inhibitors of the ATP-sensitive K+ channel (KATP) have similarly been observed to attenuate hy poxic hyperemia and pial artery dilation in the adult and newborn (Shankar and Armstead, 1995; Reid et aI., 1993; Taguchi et aI., 1994) . Recently, it has been observed that activation of K A T P channels contributes to cGMP-mediated vasodilation of pial arteries (Armstead, 1996) . It has also been observed that NO synthase inhibition attenuates the cerebral hy peremic response to adenosine in the adult rat (Dirnagl et aI., 1994) while inhibition of KATP channels attenuates the dilation of porcine coronary arteries by adenosine (Kuo and Chancellor, 1995) . On the other hand, inhibi tion of KATP channels has also been observed to only attenuate the coronary vasoactivity of adenosine ana logues and not native adenosine (Niiya et aI., 1994) . Since significant development of cerebral adenosine re ceptors, particularly in terms of density and coupling to second mes&engers may occur postnatally (Geiger et aI., 1984; Marangos et aI., 1982) , the contribution of cyclic nucleotides and KA T P channel activation to adenosine dilation in the newborn cerebral circulation is uncertain.
Therefore, the present study was designed to investi gate the role of NO, cyclic nucleotides, and activation of K A TP channels in the elicitation of adenosine's vascular response and relate these mechanisms to the contribution of adenosine to hypoxia induced pial artery dilation in the newborn pig.
MATERIALS AND METHODS
Newborn pigs (1-5 days old) of either sex were used in these experiments. They were initially anesthetized with ketamine hydrochloride (33 mg/kg i.m.) and acepromazine (3.3 mg/kg i.m.). Anesthesia was maintained with a-chloralose (30-50 mgl kg initially, supplemented with 5 mg/kg/h i.v.). A catheter was placed into the right femoral artery to record blood pressure and to obtain blood samples for determination of blood gases and pH. Another catheter was inserted into the right femoral vein for the injection of drugs and fluids. The trachea was cannu lated, and the animals were ventilated with room air. Core body temperature was monitored with a rectal probe and maintained at 37 ± 2°C with an overhead radiant heater.
For the insertion of the cranial window, the scalp was re moved and an opening was made in the skull over the parietal cortex. The dura was cut and retracted over the cut bone edge. The cranial window was placed in the hole and filled with artificial CSF of the following composition (in milligrams per liter): 220 KCl, 132 MgC12, 221 CaCI2, 7,710 NaC!, 402 urea, 665 dextrose, and 2,066 NaHC0 3 : with pH at 7.33, Pco2 of 46 mrn Hg, and a P02 of 43 mm Hg, and a temperature of 37 ± 2°C. We have shown previously that this artificial CSF does not affect the resting pial arteriolar diameter in piglets (Arm stead, 1995a,b).
Pial arteries were observed with a microscope, a television camera mounted on the microscope, and a video monitor. Ves sel diameter was measured with a video microscaler (model VPA 550, For-A-Corp, Los Angeles, CA, U.S.A.).
Experimental protocol
Diameters of pial vessels (small artery 120-160 fLm, arteri ole 50-70 fLm) were measured every minute for a IO-min ex posure period after injection under the window of artificial CSF containing no drug and after injection of CSF containing a drug. Two milliliters of CSF was flushed through a window over 30 s. Needles incorporated into the side of the window allowed infusion of CSF under the window and runoff of ex cess CSF. We measured the peak response. We waited at least 20 min after flushing the highest concentration of any drug before topically applying another agent. Hypoxia was produced by decreasing inspired oxygen sufficiently to reduce and main tain arterial P02 (Pa02) at either 34 ± 2 or 28 ± 2 mm Hg while maintaining constant pH, arterial Pc02 (Pac02)' and blood pres sure. Blood pressure was maintained via intravenous adminis tration of saline. Changes in pial artery diameter were noted every minute during the lO-min hypoxic exposure period. Time-control experiments were designed to compare the initial response to agonists to those obtained 30 min later, designated as time I and time 2 in Tables I and 2 below. A blood sample was taken after 3 min of hypoxic exposure to confirm the degree of hypoxia. The peak response was recorded after the desired level of hypoxia was achieved. Responses to hypoxia were obtained before and after the adenosine antagonists 8-phenyltheophylline (10-5 M) and adenosine deaminase (20 U/ml) (Sigma Chemical, St. Louis, MO, U.S.A). Responses to hypoxia were also obtained in the absence and presence of the K ATP channel inhibitor, glibenclamide (10-6 M) (Research Bio chemical, Natick, MA, U.S.A.) and the NO synthase inhibitor, L-NNA (Sigma). For hypoxia responses in the presence of an tagonists, the selected antagonist was topically applied 10 min before induction of hypoxia, and the subsequent effects of that probe on hypoxia-induced pial vasodilation were observed for the succeeding 10 min.
The selectivity of the adenosine antagonists was assessed by obtaining responses to adenosine and sodium nitroprusside (SNP) (10-8 , 10-6 , 10-4 M) (Sigma) before and after 8-phenyl theophylline or adenosine deaminase. Additionally, responses to adenosine were obtained in the absence and presence of L-NNA, glibenclamide, or the cAMP antagonist, Rp 8-bromo cAMPs (10-5 M) (Biolog Life Science Institute, LaJolla, CA, U.S.A.), and a CSF sample for cyclic nucleotide or opioid analysis was collected at the end of the I O-min exposure period. CSF (300 fLl) was collected by slowly infusing CSF into one side of the window and allowing the CSF under the window to drip freely into a collection tube on the opposite side.
The stock glibenclamide solution (10-3 M) was made by initially dissolving this agent in a small amount of dimethyl sulfoxide (200 fLl) and the balance in ethanol. This vehicle was then diluted 1: 1000 in CSF to make the working solution. This CSF-dimethyl sulfoxide-ethanol vehicle had no effect on pial artery diameter (157 ± 6 vs. 158 ± 8 fLm, n = 5). Appropriate aliquots of the vehicle for all other agents (0.9% saline) were added to the CSF infused under the window. This CSF vehicle had no effect on pial artery diameter, as reported previously (Armstead, 1995a,b) .
cGMP and cAMP analysis CSF samples collected after a lO-min exposure to a drug were analyzed for cGMP or cAMP using scintillation proximity assay methods. Commercially available kits for cGMP and cAMP (Amersham, Arlington Heights, IL, U.S.A.) were used. Briefly, this assay determines cyclic nucleotide concentration for binding to an antiserum, which has a high specificity for either cGMP or cAMP. The antibody-bound cyclic nucleotide is then reacted with an anti-rabbit second antibody bound to fluoromicrospheres. Labeled cyclic nucleotide bound to the pri mary rabbit antibody can then be measured by determining the amount of light emitted by the fluoromicrospheres using a beta scintillation counter. All unknowns were assayed at two dilu tions. The concentration of unlabeled cyclic nucleotides is cal culated from the standard curve via linear regression analysis.
Opioid analysis
CSF samples were immediately acidified with 1 N acetic acid to prevent peptide degradation, rapidly frozen, and stored at -20De. Radioimmunoassay kits for methionine enkaphalin and leucine enkephalin are commercially available (Inc star, Stillwater, MN, U.S.A.; Peninsula, Belmont, CA, U.S.A.). The radioimmunoassay uses simultaneous addition of sample, rab bit anti-opioid antibody, and the 1 2 51 derivative of the opioid.
After an overnight incubation at 4 DC, free opioid was separated from opioid bound to antibody by the addition of saturated ammonium sulfate in the presence of rabbit carrier )I-globulin. Following centrifugation at 760 g for 10 min, the supernate was decanted and the pellet counted using a -y-scintillation counter. All samples and standards were assayed in duplicate. Data are calculated as % BlEo versus concentration, where % B!Bo = (avg. cpm of sample -avg. cpm of nonspecific binding tube)! Bo x 100 and Bo = avg. cpm of total binding tube -avg. cpm of nonspecific binding tube. We have used these methods pre viously to quantify opioid concentration in periarachnoid cor tical CSF (Armstead et al., 1991) .
Statistical analysis
Pial arteriolar diameter, systemic arterial pressure, cyclic nucleotide, and opioid levels were evaluated using analysis of variance for repeated measures. If the value was significant, the Fisher test was performed. An a level of p < 0.05 was consid ered significant in all statistical tests. Values are presented as means ± SD of absolute values or as percentages of change from control values. Data presented as percent change were compared by nonparametric means using the Wilcoxon signed rank test.
RESULTS

Influence of adenosine antagonists on hypoxia-induced pial artery dilation
Moderate hypoxia (P a02 = 34 ± 2 mm Hg) and severe hypoxia (P a02 = 28 ± 2 mm Hg) elicited reproducible pial small artery (120-160 fLm) and arteriole (50-70 fLm) vasodilation (Table 1 , n = 5).
Hypoxia-induced vasodilation of the small pial arter ies and arterioles was attenuated by topical 8-phenylthe ophylline (10-5 M) or adenosine deaminase (20 U/ml) (Figs. 1 and 2; n = 5). On a percentage basis, 8-phen yltheophylline attentuated the moderate hypoxia-induced vasodilation of small arteries and arterioles by 27 ± 10 and 29 ± 9%, respectively, while adenosine deaminase attenuated dilation of these vessels by 24 ± 9 and 28 ± 7%, respectively. Vasodilation due to severe hypoxia was decreased in small arteries and arterioles in the pres ence of 8 phenyltheophulline by 37 ± 9 and 47 ± 8% and by 41 ± 12 and 45 ± 6% in the presence of adenosine deaminase, respectively. Adenosine (10-8 , 10-6 , 10-4 M) elicited reproducible vasodilation in pial small arteries and arterioles (Table 2, n = 5). These increases in vessel diameter were blunted in the presence of either 8-phenyltheophylline or aden osine deaminase (Figs. 3 and 4; n = 5). These antago nists had no effect on pial small artery diameter (129 ± 12 vs. 132 ± 11 fLm for 8-phenyltheophylline and 142 ± 12 vs. 146 ± 16 fLm for adenosine deaminase, respec tively, n = 5). Similarly, these antagonists had no effect on pial arteriole diameter (6 1 ± 4 vs. 62 ± 4 fLm for 8-phenyltheophylline and 58 ± 30 vs. 59 ± 4 fLm for adenosine deaminase, respectively, n = 5). Finally, these antagonists had no effect on the dilation produced by SNP (10-8 , 10-6 , 10-4 M) (data not shown).
Role of NO in adenosine-induced pial artery dilation
Adenosine-induced pial vasodilation was attenuated by L-NNA (10-6 M) ( Fig. 5a , n = 6). Adenosine (10-8 , 10-6 , 10-4 M) was associated with 1.3 ± 0.1-, 1.7 ± 0.1-, and 2.1 ± 0.3-fold increases in cortical peri arachnoid CSF cOMP, which L-NNA attenuated (Fig. 5b , n = 6). L-NNA decreased resting CSF cOMP concentration ( Fig.  5b) and decreased pial artery diameter from 170 ± 8 to 160 ± 8 fLm, n = 5. Adenosine-induced pial dilution was associated with increased CSF cGMP concentration, as described above. Additionally, vascular responses to adenosine were at tenuated by 1{p 8-bromo cGMPs (10-5 M), a cGMP an tagonist (Fig. 6, n = 5) . Similarly, adenosine also in creased CSF cAMP, and vascular responses to adenosine were attenuated by the cAMP antagonist, Rp 8-bromo cAMPs (10-5 M) ( Fig. 7a,b ). Neither Rp 8-bromo cGMPs nor Rp 8-bromo cAMPs had any effect on pial artery diameter (149 ± 14 vs. 145 ± 18 fLm for Rp 8-bromo cGMPs and 150 ± 10 vs. 151 ± 11 fLm for Rp 8-bromo cAMPs, respectively, n = 5). 
Influence of glibenclamide on adenosine-induced pial artery dilation
Adenosine-induced pial artery dilation was attenuated by glibenc1amide (10-6 M) ( Fig. 8 , n = 5). Gliben c1amide itself had no effect on pial artery diameter (146 ± 19 vs. 148 ± 20 fLm, n = 5).
Influence of adenosine on CSF opioid concentration
Topical adenosine had no effect on CSF methionine en kephalin or leucine enkephalin concentration (Table 3 , n = 6).
Blood chemistry and mean arterial blood pressure
Blood chemistry and mean arterial blood pressure val ues were obtained at the beginning and end of all nor moxia experiments as well as during normoxia and hy poxia in experiments designed to characterize the role of adenosine in hypoxia-induced pial artery dilation. Hy- poxia decreased P a02 as expected, whereas the pH, P aC0Z, and mean arterial blood pressure values were un changed (Table 4 ).
DISCUSSION
Results of the present study show that hypoxic pial dilation was attenuated by the antagonists of adenosine action 8-phenyltheophyUine and adenosine deaminase. Both probes blocked adenosine-induced pial dilation. These data indicate that adenosine contributes to pial artery dilation during moderate and severe hypoxia. When compared to other mechanisms that contribute to hypoxic pial dilation in the newborn pig, however, the role of adeno�ine appears to be rather modest. For ex ample, L-NNA decreased moderate hypoxia-induced small pial artery dilation by 47 ± 4% (Armstead, 1995a) , while [3-funaltrexamine, a j.L opioid antagonist, decreased this response by 38 ± 4% (Armstead, 1995a) . Addition ally, moderate hypoxic pial artery dilation was decreased by 43 ± 2% in the presence of the 8 J opioid antagonist, BNTX or 64 ± 7% in the presence of the 82 antagonist, naltrindole (Armstead, 1995b) . In contrast, in the present study the adenosine receptor antagonist, 8-phenyltheoph-yUine, decreased the pial response to moderate hypoxia by only 27 ± lO%. Moreover, this adenosine antagonist did not further decrease the pial response during severe hypoxia (24 ± 9%), a possibility observed with antago nists of other vasoactive systems (i.e., BNTX, 72 ± 12 vs. 43 ± 2%). While differences between the present and previous studies concerning the role of adenosine in hy poxic cerebrovasodilation could be due to age (Dora et aI., 1984; Reid et aI., 1995) , such differences using the same age and species (McPhee and Maxwell, 1987) could also be due to choice of adenosine antagonist, con centration, and route of administration.
The present study was also designed to determine the second messengers involved in the elicitation of adeno sine's vascular response and relate these mechanisms to the contribution of adenosine to hypoxic pial dilation. Results of this study show that adenosine's dilation is associated with increased cortical peri arachnoid CSF cGMP concentration. Additionally, L-NNA and Rp 8-bromo cGMPs, a cGMP antagonist (Nazakawa and Imai, 1994) , attenuated adenosine-induced dilation. Pre vious studies in the pig show that L-NNA blocked re sponses to acetylcholine, while responses to SNP were unchanged, indicating that L-NNA is a selective NO syn thase inhibitor (Armstead et aI., 1994) . Since NO is thought to elicit dilation via activation of soluble gua nylate cyclase (Ignarro, 1990) , these data indicate that NO contributes to adenosine pial dilation via release of cGMP. Recently it has been observed that activation of KATP channels contributes to cGMP-mediated vasodila tion of pial arteries (Armstead, 1996) . Results of this study show that adenosine pial dilation was attenuated by the KATP channel antagonist, glibenclamide, in a concen tration previously observed to block responses to the KATP channel agonist, cromakalim (Shankar and Arm-
� 'a stead, 1995). Therefore, these data suggest that adeno sine elicits pial dilation, at least in part, via release of NO, which activates KA T P channels through a cGMP dependent mechanism. Since adenosine dilation was also associated with elevated CSF cAMP concentration and that vascular response was attenuated by RP 8-bromo cAMPs, a cAMP antagonist (Wang et aI., 1991) , data from this study indicate that cAMP also contributes to adenosine pial dilation. Taken together, then, these data indicate that the mechanism for adenosine dilation in the cerbral circulation is multifactorial, involving NO, cGMP, cAMP, and activation of KA T P channels.
In the context of previous studies, however, results of the present investigation indicating that NO and cGMP are involved in the pial dilation response to adenosine are somewhat surprising. For example, responses to adeno sine were unchanged after endothelial layer removal from cat middle cerebral arteries in vitro (Conde et aI., 1991) or after methylene blue application to cat pial ar teries in vivo (Haberl et aI., 1990) . Furthermore, dilation to adenosine was unchanged by the NO synthase inhibi tor, L-NMMA, in isolated rat intracerebral arterioles (Ngai and Winn, 1995) and in pial arteries of the cat in vivo (Wei et aI., 1992) . However, the suggested role of NO in adenosine cerebrovascular dilation is not without precedent since Dirnagl et aI. (1994) have observed that another NO synthase inhibitor, L-NNA, reduced the ce rebral blood flow response to adenosine in the rat. In the coronary circulation, similar observations indicate that NO was also involved in the vascular response to aden osine (Kuo and Chancellor, 1995; Vials and Burnstock, 1993) . Therefore, although controversial, there is evi dence for the role of NO in adenosine-induced dilation.
Reasons for such divergent observations are uncertain but could be due to differences in methodology, type and dose of NO synthase inhibitor used, species, and/or age differences.
Having identified mechanisms involved in adenosine pial dilation, an attempt was then made to relate these data to the contribution of adenosine to hypoxic pial dilation. Since activation of KAT P channels has been ob served to contribute to hypoxic pial dilation (Shankar and Armstead, 1995) , data from the present study sug gest that, at least in part, adenosine's role in hypoxic dilation involves the release of NO, which activates KA T P channels through a cGMP-dependent mechanism.
It was initially hypothesized that opioids could serve as intermediates in this process since it was observed that the opioids methionine enkephalin and leucine enkeph alin contribute to hypoxia-induced pial dilation through activation of K ATP channels (Shankar and Armstead, 1995) . Additionally, cGMP has recently been observed to increase CSF methionine enkephalin and leucine en kephalin concentration (Wilderman and Armstead, 1996) . Therefore, adenosine could activate K ATP chan nels via the sequential release of cGMP and opioids. could be an indirect consequence of elevated cAMP as a result of cross-talk between cyclic nucleotide-meta bolizing systems at the level of their synthesis or degra dation (Vigne et al., 1994) . For example, it has been suggested that an increase in cAMP levels would com petitively prevent cGMP breakdown at the level of phos phodiesterase (Hernandez et aI., 1994; Vigne et aI., 1994) .
Furthermore, it has been recently observed that for skolin, a direct activator of adenylate cyclase, induced pial arterial dilation and increased CSF cGMP; the vas cular and biochemical changes being attenuated by L NNA (Rebich et al., 1995) . These data suggest an asso ciation between cAMP elevation and the consequent ac tivation of NO synthase. It is presently uncertain if this possibility could account for the dual involvement of cGMP and cAMP in adenosine-induced pial arterial va sodilation. While these two cyclic nucleotides could, therefore, interact in the mediation of adenosine's con tribution to hypoxic pial dilation, they may also contrib ute to hypoxic dilation separately.
The mechanism by which hypoxia results in cerebral vasodilation has not been fully established. Studies in the past have suggested a role for the endothelium, nitric oxide, prostanoids, opioids, and vasopressin (Armstead, 1995a,b; Coyle et aI., 1993; Eisenach et aI., 1992; Fred ricks et aI., 1994; Iwamoto et aI., 1992) . The contribution of some of these systems to hypoxic vasodilation is con troversial, however, For example, NO has been observed to both contribute to hypoxic pial dilation and not con tribute to hypoxic hyperemia in the newborn pig (Arm-stead, 1995a; Ichord et aI., 1994) . Such controversial findings could be due to differences in methodology or types and dose of No synthase inhibitor used. Recently, the K ATP channel inhibitors tolbutamide and gliben clamide have been observed to attenuate hypoxia induced hyperemia and pial artery dilation, suggesting a role for K ATP channel activation in that vascular response (Reid et aI., 1993; Taguchi et aI., 1994) . Additional stud ies have attempted to link the activation of K ATP chan nels to other vasoactive systems as contributing factors to hypoxia-induced vasodilation. For instance, adenosine has been observed to contribute to hypoxia-induced va sodilation of the isolated perfused rabbit heart through activation of K ATP channels (Nakhostine and LaMon tagne, 1993). In contrast, adenosine does not appear to contribute to hypoxia-induced pial artery dilation via ac tivation of K ATP channels in the adult rabbit (Taguchi et aI., 1994) . In another study, an endothelium-derived cy clooxygenase product has been suggested to link K ATP channel activation to hypoxia-induced dilation of iso lated rat middle cerebral arteries (Fredricks et aI., 1994) .
Results of the present study are the first to link adenosine to K ATP channel activation in its contribution to hypoxia induced pial artery dilation in the newborn. Differences between this study and observations made in the adult rabbit (Tagucqi et aI., 1994) , may be due to species and/or age-dependent variables.
In conclusion, results of this study show that NO, cOMP, cAMP, and activation of K ATP channels all con tribute to adenosine-induced pial dilation. Furthermore, these data suggest that adenosine contributes to hypoxia induced dilation via cAMP and activation of K ATP chan nels by NO and cOMPo
